EBMT 2019 | First-in-human bispecific CAR T-cell therapy for R/R non Hodgkin lymphoma

Nirav Niranjan Shah

Nirav Niranjan Shah, MD, from the Medical College of Wisconsin, Milwaukee, WI, delivers updates from the first-in-human Phase I dose-escalation study of bispecific anti-CD19, anti-CD20 CAR T-cells (CAR-20.19-T) for relapsed/refractory non-Hodgkin Lymphoma (NCT03019055). Dr Shah was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

Share this video  
Similar topics